JAK inhibitor PDUFA dates extended again as safety review continues; Stemson secures $15M to cure hair loss
Two more supplemental new drug applications have been delayed again — this time from AbbVie, and the partners Eli Lilly and Incyte — as the FDA continues …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.